Our Personal Injury & Clinical Negligence teams have created a compelling channel for lawyers which will provide news, insights, and some personality to complex legal cases.

Our podcasts convey thought leadership throughout our episodes, share insights, and simplify and discuss implications of key cases in personal injury and clinical negligence law. We also aim to save solicitors some time in summarising and explaining developments.

In this final podcast in our mini-series of three podcasts on the fundamentals of oncology cases, eminent Oncologist and go-to medicolegal expert Professor Pat Price and Clinical Negligence barrister Rachel Segal focus their discussion on the theme of Treatment in cancer, sharing with listeners important insights into clinician and individual patient treatment decisions, including the role of Multidisciplinary Team Meetings for primary cancers, issues around treatment pathway options, consent (and second opinions), and shifts in recent history in treatment developments and timelines.

As many of listeners will know, Professor Pat Price is a Consultant Oncologist and a go-to medicolegal expert for both claimants and defendants in clinical negligence litigation. Professor Price is a pioneer in PET molecular imaging, Visiting Professor at Imperial College London and, among many other activities, runs the charity Radiotherapy UK. She has been instrumental in establishing the Medicolegal Knowledge Partnership (MLKP) – an important collaborative initiative aiming to improve patient care and legal outcomes in healthcare matters. Here is a link to Medicolegal Knowledge Partnership (MLKP) which lawyers can join for free. Find out more here.

Dr Rachel Segal is a specialist personal injury and clinical negligence barrister advising and representing claimants and defendants in litigation, and interested persons in healthcare-related inquests. Rachel’s busy practice spans the spectrum of clinical negligence, and within her many oncology cases she is particularly experienced in matters involving delayed diagnosis of primary and metastatic breast, colorectal and prostate cancers. She is ranked as a leading junior in her specialisms in both The Legal 500 and Chambers UK. Find out more here.